Scarica l'app Stockscreener
191.83
1.18%
-1.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$193.81
Aprire:
$194.07
Volume 24 ore:
608.47K
Relative Volume:
0.31
Capitalizzazione di mercato:
$28.13B
Reddito:
$9.69B
Utile/perdita netta:
$1.61B
Rapporto P/E:
17.49
EPS:
10.9652
Flusso di cassa netto:
$2.26B
1 W Prestazione:
+8.35%
1M Prestazione:
+2.08%
6M Prestazione:
+46.56%
1 anno Prestazione:
+34.36%
Intervallo 1D:
$191.03
$195.72
Intervallo di 1 settimana:
$177.10
$202.41
Portata 52W:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
191.66 | 28.44B | 9.69B | 1.61B | 2.26B | 10.97 |
|
LLY
Lilly Eli Co
|
1,032.13 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.63 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
224.64 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
158.43 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.08 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
BIIB: Wedbush Raises Price Target to $187 While Maintaining Neut - GuruFocus
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating - marketscreener.com
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook - Yahoo Finance
State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next - Yahoo Finance
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - ACN Newswire
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point - simplywall.st
Analyst JP Morgan Raises Price Target for Biogen (BIIB) to $230 - GuruFocus
Biogen (BIIB) Sees Raised Price Target by Canaccord Genuity | BI - GuruFocus
Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView
BIIB: BMO Capital Elevates Price Target While Maintaining Market Perform Rating | BIIB Stock News - GuruFocus
BIIB Analysts Maintain Rating, Significant Price Target Increase by TD Cowen | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 - MarketBeat
Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ - GuruFocus
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says - marketscreener.com
Guggenheim Raises Price Target on Biogen (BIIB) to $246 | BIIB S - GuruFocus
Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth - Investing.com
BMO Capital raises Biogen stock price target to $196 on Spinraza potential - Investing.com
BIIB: RBC Capital Increases Biogen's Price Target to $233 on Sus - GuruFocus
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' - Benzinga
Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI - GuruFocus
Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto - GuruFocus
Truist Securities Raises Price Target for Biogen (BIIB) to $193 | BIIB Stock News - GuruFocus
Biogen stock price target raised to $215 from $175 at TD Cowen - Investing.com
Biogen stock price target raised to $233 from $217 at RBC Capital - Investing.com
Piper Sandler raises Biogen stock price target to $177 on Leqembi ramp - Investing.com
Biogen’s much anticipated Tau readout in Alzheimer’s will spur more questions - PharmaLive
BIIB Stock Receives Raised Price Target from HC Wainwright & Co. - GuruFocus
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating - marketscreener.com
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
Guggenheim raises Biogen stock price target to $246 on pipeline potential - Investing.com
Canaccord Genuity raises Biogen stock price target on strong Q4 results - Investing.com
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating - marketscreener.com
Biogen stock price target raised to $228 from $194 at H.C. Wainwright - Investing.com
Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating - marketscreener.com
Baird reiterates Outperform rating on Biogen stock, maintains $250 price target - Investing.com
Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating - marketscreener.com
Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating - marketscreener.com
Biogen FY25 Earnings: Stable EPS, Amid Pressure From Multiple Sclerosis Franchise (BIIB) - Seeking Alpha
TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating - marketscreener.com
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi - Stocktwits
Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis… - marketscreener.com
The Truth About Biogen Inc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China - marketscreener.com
Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China - TradingView
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Biogen
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - AOL.com
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.79%
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):